Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.14 billion
- Book Value:
- Revenue TTM:
- $507.66 million
- Operating Margin TTM:
- Gross Profit TTM:
- $423.58 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Novocure Ltd had its IPO on 2015-10-02 under the ticker symbol NVCR.
The company operates in the Healthcare sector and Medical Devices industry. Novocure Ltd has a staff strength of 1,320 employees.
Shares of Novocure Ltd opened at $20.24 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $19.38 - $20.28, and closed at $19.95.
This is a -2.64% slip from the previous day's closing price.
A total volume of 1,147,965 shares were traded at the close of the day’s session.
In the last one week, shares of Novocure Ltd have slipped by -10.5%.
Novocure Ltd's Key Ratios
Novocure Ltd has a market cap of $2.14 billion, indicating a price to book ratio of 17.9456 and a price to sales ratio of 14.357.
In the last 12-months Novocure Ltd’s revenue was $507.66 million with a gross profit of $423.58 million and an EBITDA of $-180140000. The EBITDA ratio measures Novocure Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Novocure Ltd’s operating margin was -37.4% while its return on assets stood at -10.22% with a return of equity of -40.67%.
In Q2, Novocure Ltd’s quarterly earnings growth was a negative -6% while revenue growth was a negative 10.5%.
Novocure Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.6 per share while it has a forward price to earnings multiple of 909.0909 and a PEG multiple of -0.47. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novocure Ltd’s profitability.
Novocure Ltd stock is trading at a EV to sales ratio of 14.01 and a EV to EBITDA ratio of -119.4298. Its price to sales ratio in the trailing 12-months stood at 14.357.
Novocure Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.16 billion
- Total Liabilities
- $150.09 million
- Operating Cash Flow
- Capital Expenditure
- $6.93 million
- Dividend Payout Ratio
Novocure Ltd ended 2023 with $1.16 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.16 billion while shareholder equity stood at $415.68 million.
Novocure Ltd ended 2023 with $0 in deferred long-term liabilities, $150.09 million in other current liabilities, in common stock, $-888939000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $156.98 million and cash and short-term investments were $940.82 million. The company’s total short-term debt was $67,551,000 while long-term debt stood at $567.15 million.
Novocure Ltd’s total current assets stands at $1.07 billion while long-term investments were $0 and short-term investments were $783.84 million. Its net receivables were $91.14 million compared to accounts payable of $82.54 million and inventory worth $33.02 million.
In 2023, Novocure Ltd's operating cash flow was $-13897000.00 while its capital expenditure stood at $6.93 million.
Comparatively, Novocure Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Novocure Ltd stock is currently trading at $19.95 per share. It touched a 52-week high of $120.03 and a 52-week low of $120.03. Analysts tracking the stock have a 12-month average target price of $58.71.
Its 50-day moving average was $31.67 and 200-day moving average was $61.73 The short ratio stood at 6.04 indicating a short percent outstanding of 0%.
Around 122% of the company’s stock are held by insiders while 8556.1% are held by institutions.
Frequently Asked Questions About Novocure Ltd
Similar Industry Stocks (Medical Devices)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.